Company profile
Accustem Sciences Inc.
OTC: ACUT · Healthcare · Biotechnology
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH 20DQ —GM —SS 20
v0.1 · 35/100 weight · pillars only
↑ market scale, Altman-Z · ↓ Piotroski F, listing tenure
Methodology →Revenue TTM
$98.4k
Rev growth YoY (TTM)
+2610.7%
Net income (FY)
-$1.8M
Employees
4
as of 2026-09-23
Market cap
$1.9M
as of 2026-09-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$1.8M-$1.8M2025
Operating income-$1.8M-$1.8M2025
Total assets$1.5M$1.5M2025
Liabilities$5.0M$5.0M2025
Equity-$3.4M-$3.4M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Accustem Sciences Inc.’s financial profile?
Accustem Sciences Inc. earned -$1.8M in FY2025 net income.
Peers · Healthcare
Enzolytics Inc.——Shuttle Pharmaceuticals Holdings, Inc.——Yuka Group, Inc.——TransCode Therapeutics, Inc.——Restart Life Sciences Corp.——Algernon Pharmaceuticals Inc.——Neighbors
New York →Key facts
CEOWendy E. Blosser
SectorHealthcare
IndustryBiotechnology
HeadquartersNew York City, NY
ExchangeOTC: ACUT
Employees4
IPO date2022-03-03
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.